Using Atovaquone to treat platinum-resistant ovarian cancer
Official title: Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Run by Emory University · NCT05998135 · Data updated 2026-11-12
This study is testing if atovaquone, a medication usually used for infections, can help people with platinum-resistant ovarian cancer live longer and feel better.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 28 (estimated) |
| Sponsor | Emory University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Atlanta, Georgia) |
| Status | Recruiting |
| Started | November 9, 2023 |
| Main results expected | March 24, 2027 |
| Study ends | June 30, 2028 |
| Registry record updated | October 1, 2026 |
| Trial ID | NCT05998135 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with platinum-resistant high-grade serous ovarian cancer who have experienced disease progression within six months of their last platinum-based chemotherapy.
✕Probably not a fit
Patients under 18, pregnant or breastfeeding individuals, and those unable to provide consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase II trial evaluates the effectiveness of atovaquone, a medication typically used for treating infections, in patients with platinum-resistant ovarian cancer. The study aims to determine the progression-free survival of participants and assess clinical benefits such as response rates and overall survival. Patients will receive atovaquone orally and undergo imaging and biopsies to monitor their condition throughout the trial. The study also investigates the drug's impact on tumor immune response and specific gene transcription.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with limited choices due to platinum resistance.
How similar studies have gone: While the use of atovaquone for this indication is novel, other studies have explored repurposing existing medications for cancer treatment with varying degrees of success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy * Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * There will be no limitations on number of prior lines of therapy * Trial is open to non-English speaking patients * Trial is open to patients referred from community practice Exclusion Criteria: * Patients who are \< 18 years old * Patients who are pregnant or breastfeeding (due to cancer of their reproductive organs, patients enrolled in the trial are unable to conceive) * Patients who are incarcerated * Patients who are unable to provide consent / lack decision-making capacity
Where it's running
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States Recruiting
Study contacts
- Principal investigator: Namita Khanna, MD, MSPH — Emory University Hospital/Winship Cancer Institute
- Study coordinator: Namita Khanna, MD, MSPH
- Email: namita.khanna@emory.edu
- Phone: 404-778-3401
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Uterine Lavage to Screen BRCA Carriers for Ovarian Cancer Risk
This study tests whether rinsing the uterus with saline and analyzing the collected cells can help detect early signs of ovarian cancer in women with BRCA mutations who are planning risk-reduction surgery.
-
Testing Olaparib with or without Bevacizumab for Ovarian Cancer Treatment
This study is testing if a new cancer treatment called olaparib, alone or with another drug called bevacizumab, can help women with advanced ovarian cancer live longer without their cancer getting worse.
-
Using MUC1-activated T cells to treat resistant ovarian cancer
This study is testing a new treatment using specially designed immune cells to see if they can help people with tough-to-treat ovarian cancer feel better and improve their health.
-
Using modified immune cells to treat platinum-resistant ovarian cancer
This study is testing whether modified immune cells can help people with platinum-resistant ovarian cancer fight their tumors.
-
Combining ONC201 with Paclitaxel for Ovarian Cancer Treatment
This study is testing if combining a new drug called ONC201 with paclitaxel can help people with hard-to-treat ovarian cancer feel better and live longer.
-
Testing ZM008 alone and with Pembrolizumab in patients with advanced solid tumors
This study is testing a new treatment called ZM008, alone and with another drug called Pembrolizumab, to see if it can help patients with advanced solid tumors who have run out of other treatment options.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.